JP2014518228A - 高速溶解速度を有する非晶質トモキシプロールとシクロデキストリンとの複合体およびこの調製方法 - Google Patents

高速溶解速度を有する非晶質トモキシプロールとシクロデキストリンとの複合体およびこの調製方法 Download PDF

Info

Publication number
JP2014518228A
JP2014518228A JP2014517574A JP2014517574A JP2014518228A JP 2014518228 A JP2014518228 A JP 2014518228A JP 2014517574 A JP2014517574 A JP 2014517574A JP 2014517574 A JP2014517574 A JP 2014517574A JP 2014518228 A JP2014518228 A JP 2014518228A
Authority
JP
Japan
Prior art keywords
tomoxyprol
cyclodextrin
complex
hydroxypropyl
amorphous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014517574A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014518228A5 (enExample
Inventor
ミラネーゼ，アルベールト
ネブローニ，マリーノ
カツラノ，ルチア
Original Assignee
フオンダツイオーネ・イステイトウート・インスブリコ・デイ・リチエルカ・ペル・ラ・ビータ
フオンダツイオーネ・カリプロ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フオンダツイオーネ・イステイトウート・インスブリコ・デイ・リチエルカ・ペル・ラ・ビータ, フオンダツイオーネ・カリプロ filed Critical フオンダツイオーネ・イステイトウート・インスブリコ・デイ・リチエルカ・ペル・ラ・ビータ
Publication of JP2014518228A publication Critical patent/JP2014518228A/ja
Publication of JP2014518228A5 publication Critical patent/JP2014518228A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Rheumatology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2014517574A 2011-07-01 2012-06-14 高速溶解速度を有する非晶質トモキシプロールとシクロデキストリンとの複合体およびこの調製方法 Pending JP2014518228A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI20111235 2011-07-01
ITMI2011A001235 2011-07-01
PCT/EP2012/061261 WO2013004462A1 (en) 2011-07-01 2012-06-14 A complex of amorphous tomoxiprole and cyclodextrin with fast dissolution rate and process for the preparation thereof

Publications (2)

Publication Number Publication Date
JP2014518228A true JP2014518228A (ja) 2014-07-28
JP2014518228A5 JP2014518228A5 (enExample) 2015-04-02

Family

ID=44533012

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014517574A Pending JP2014518228A (ja) 2011-07-01 2012-06-14 高速溶解速度を有する非晶質トモキシプロールとシクロデキストリンとの複合体およびこの調製方法

Country Status (6)

Country Link
US (1) US8791269B2 (enExample)
EP (1) EP2726106B1 (enExample)
JP (1) JP2014518228A (enExample)
CA (1) CA2835232C (enExample)
ES (1) ES2547920T3 (enExample)
WO (1) WO2013004462A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112334494A (zh) 2018-06-29 2021-02-05 罗盖特公司 新颖的羟丙基-β-环糊精及其生产方法
FR3083234B1 (fr) * 2018-06-29 2020-11-27 Roquette Freres Nouvelles hydroxypropyl-beta-cyclodextrines et leurs procedes de preparation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11240833A (ja) * 1997-11-26 1999-09-07 Pfizer Prod Inc ドロロキシフェン医薬組成物
JP2006052172A (ja) * 2004-08-12 2006-02-23 Mikasa Seiyaku Co Ltd ピラゾロン系製剤
JP2008523096A (ja) * 2004-12-10 2008-07-03 スーパージェン インコーポレイテッド デシタビン医薬製剤
JP2008529999A (ja) * 2005-02-04 2008-08-07 ハンミ ファーム． シーオー．， エルティーディー． 溶解性が増加した非晶質タクロリムス固体分散体及びこれを含む医薬組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0012866B1 (en) 1978-12-21 1983-01-19 Gruppo Lepetit S.P.A. New 3h-naphtho(1,2-d)imidazoles, processes for preparing them, compounds for use as antiinflammatory and antimicrobial agents and compositions for that use containing them
EP1219306A1 (en) 2000-12-29 2002-07-03 Nicox S.A. Compositions comprising cyclodextrins and NO- releasing drugs
ATE359827T1 (de) 2002-06-17 2007-05-15 Chiesi Farma Spa Prozess für die vorbereitung von piroxicam: beta- cyclodextrin einschlusskomplexe

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11240833A (ja) * 1997-11-26 1999-09-07 Pfizer Prod Inc ドロロキシフェン医薬組成物
JP2006052172A (ja) * 2004-08-12 2006-02-23 Mikasa Seiyaku Co Ltd ピラゾロン系製剤
JP2008523096A (ja) * 2004-12-10 2008-07-03 スーパージェン インコーポレイテッド デシタビン医薬製剤
JP2008529999A (ja) * 2005-02-04 2008-08-07 ハンミ ファーム． シーオー．， エルティーディー． 溶解性が増加した非晶質タクロリムス固体分散体及びこれを含む医薬組成物

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AAPS PHARMSCITECH, 2010, VOL.11, NO.2, PP.885-893, JPN6017004816, ISSN: 0003499825 *
CHEM. PHARM. BULL., 2010, VOL.58, NO.10, PP.1313-1319, JPN6017004811, ISSN: 0003499823 *
DRUG DISCOV. THER., 2010, VOL.4, NO.2, PP.70-76, JPN6017004812, ISSN: 0003499824 *
EUR. J. PHARMA. SCI., 1997, VOL.5, NO.1, P.23-30, JPN6015047678, ISSN: 0003203843 *
J. LIQUID CHROMATOGRAPHY, 1984, VOL.7, NO.10, P.2093-2101, JPN6015047677, ISSN: 0003203842 *
J. PHARM. SCI., 2009, VOL.98, NO.1, PP.229-238, JPN6017004821, ISSN: 0003499826 *

Also Published As

Publication number Publication date
ES2547920T3 (es) 2015-10-09
CA2835232A1 (en) 2013-01-10
US20140128343A1 (en) 2014-05-08
WO2013004462A1 (en) 2013-01-10
US8791269B2 (en) 2014-07-29
EP2726106A1 (en) 2014-05-07
EP2726106B1 (en) 2015-07-29
CA2835232C (en) 2017-02-14

Similar Documents

Publication Publication Date Title
KR102150383B1 (ko) 안지오텐신 ii 수용체 길항제 대사물질과 nep 억제제의 화합물, 및 이의 제조 방법
TW200808726A (en) Novel polymorph forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine
WO2009136408A1 (en) Synergistic pharmaceutical cocrystals
TW202200594A (zh) 一種glp-1受體激動劑的晶型a及其製備方法
US20200165190A1 (en) Amorphous Form of Vilanterol Trifenatate and Processes for the Preparation Thereof
KR101962189B1 (ko) 아리피프라졸의 공결정 및 그의 제조방법
JP2009514856A (ja) 医薬品ガリウム組成物及び方法
EP2726106B1 (en) A complex of amorphous tomoxiprole and cyclodextrin with fast dissolution rate and process for the preparation thereof
CN103936808A (zh) 17β雌二醇的异烟酰胺共结晶及其制备方法和应用
US20140163071A1 (en) Bioavailable compositions of amorphous piperidinyl compounds
JP6908657B2 (ja) ４−［２−ジメチルアミノ−１−（１−ヒドロキシシクロヘキシル）エチル］フェニル４−メチルベンゾエートヒドロクロリドの多形体、それらを作製する方法及びそれらの使用
CN103951725A (zh) 17β雌二醇的哌嗪共结晶及其制备方法和应用
CN102282125A (zh) 新方法和纯的多晶型物
CN115197152B (zh) 一种奥拉帕尼药物共晶及其制备方法和应用
CN113402390B (zh) 一种阿司匹林药物共晶体及其制备方法和应用
CN105384730A (zh) 依帕列净的晶型及其制备方法、药物组合物和用途
CN105753869B (zh) 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
EP3099294B1 (en) Pharmaceutical composition including 5-{4-(aminosulfonyl)phenyl}-2,2-dimethyl-4-(3-fluorophenyl)-3(2h)-furanone and capsule formulation including the pharmaceutical composition
Nagasamy Venkatesh et al. Dissolution enhancement of diacerein using water soluble carrier by solid dispersion technology
WO2018078383A1 (en) Pharmaceutical composition comprising amorphous selexipag
KR102709767B1 (ko) 약학적 화합물, 이를 만드는 방법 및 의약품으로서의 용도
RU2831569C1 (ru) Композиция на основе противогрибкового средства и модифицированного циклодекстрина
JP2014518228A5 (enExample)
WO2025264950A1 (en) Crystalline dihydrotetrabenazine and the method thereof
EA052760B1 (ru) Супрамолекулярное соединение 1-n-[4-(6,7-диметоксихинолин-4-ил)оксифенил]-1-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида (s)–малата и лактозы 1:1, способы его получения и композиция

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160530

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20161209

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170110

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20170217